Zacks Investment Research upgraded Atara Biotherapeutics Inc (NASDAQ:ATRA) to Hold in a report released today.
- Updated: September 17, 2016
Displaying a price of $23.00, Atara Biotherapeutics Inc (NASDAQ:ATRA) traded 0.63% higher on the day. The last stock close is up 3.18% from the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same time period. ATRA has recorded a 50-day moving average of $21.94 and two hundred day average of $19.93. 279,612 shares of the stock traded hands, up from ann average volume of 211,250
Zacks Investment Research has upgraded Atara Biotherapeutics Inc(NASDAQ:ATRA) to Hold in a report released 8/19/2016.
On 8/19/2016, Citigroup released a statement for Atara Biotherapeutics Inc(NASDAQ:ATRA) lowered the target price from $10.00 to $8.00 that indicated a possible downside of -0.65%.
See Graph Below:
In addition to Zacks Investment Research reporting it’s price target, a total of 5 brokers have issued a report on the company. The 12-month target is $28.60 with three firms rating the stock a strong buy, one firm rating the company a buy, one analyst rating the stock a hold, 0 rating the company to underperform, and finally one brokerage rating the stock as sell.
Atara Biotherapeutics Inc has a 52 week low of $13.31 and a 52 week high of $49.94 and has a total market value of $0.0.
Brief Synopsis About Atara Biotherapeutics Inc (NASDAQ:ATRA)
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, and a humanized antibody targeting myostatin.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.